Molecular Diagnostics Market Set To Grow To $11bn By 2021

14 August 2018
Pharma

Visiongain has launched a new pharma report The Molecular Diagnostics (MDx) Market Forecast 2017-2027: Infectious Disease Testing, Oncology Testing, Blood Screening, Genetic Testing, Tissue Typing

Molecular diagnostics is a fast-growing and rapidly evolving sector of the IVD market, made possible by the growing understanding of the human genome. Molecular diagnostics tests have also led to the emerging field of companion diagnostics, in which a MDx test is used to identify whether a specific therapy is likely to be effective for an individual patient. The market for MDx is growing rapidly due to increasing biomarker discover and adoption rates, but its growth is limited by several regulatory and reimbursement issues.

The lead analyst of the report commented “There will be increasing adoption of molecular diagnostics over the forecast period as the benefits of increasing accuracy and speed of diagnosis become increasingly apparent. Another driver for the MDx industry will be the advent of Point-Of-Care MDx testing, which will greatly increase the potential availability of molecular testing as it moves out of high and moderate complexity laboratories into primary care settings such as hospitals and physicians’ offices.

The advent of personalised healthcare is also being driven by molecular diagnostics, as the ability to better stratify patients with added genetic information will allow physicians to select treatments that have a higher chance of success in an individual patient, as well as allowing for more detailed monitoring and evaluation of disease progression”

Leading companies featured in the report include Roche Diagnostics, Qiagen, Hologic, bioMérieux, Agilent Technologies, Becton, Dickinson & Company,

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Visiongain Publishes Antiviral Drugs Treatment Market Report 2021-2031

Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral drugs R&D is driving the market growth; and rising strategic initiatives for anti-viral drugs market is another major factor propelling the market growth worldwide are some of the major factors that propel the global antiviral drugs treatment market growth.

28 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever